Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX7353 in healthy subjects
NCT02448264Phase 1Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- May 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hereditary angioedema (HAE) comparing BCX7353 with Placebo (2 arms). Primary endpoints: Adverse events at Day 21, Laboratory analyses at Day 21 and 3 more. Started May 2015; status: completed.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT02448264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02448264.